RT Journal Article
SR Electronic
T1 Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000391
DO 10.1136/jitc-2019-000391
VO 8
IS 1
A1 Ascierto, Paolo Antonio
A1 Del Vecchio, Michele
A1 Mackiewicz, Andrzej
A1 Robert, Caroline
A1 Chiarion-Sileni, Vanna
A1 Arance, Ana
A1 Lebbé, Céleste
A1 Svane, Inge Marie
A1 McNeil, Catriona
A1 Rutkowski, Piotr
A1 Loquai, Carmen
A1 Mortier, Laurent
A1 Hamid, Omid
A1 Bastholt, Lars
A1 Dreno, Brigitte
A1 Schadendorf, Dirk
A1 Garbe, Claus
A1 Nyakas, Marta
A1 Grob, Jean-Jacques
A1 Thomas, Luc
A1 Liszkay, Gabriella
A1 Smylie, Michael
A1 Hoeller, Christoph
A1 Ferraresi, Virginia
A1 Grange, Florent
A1 Gutzmer, Ralf
A1 Pikiel, Joanna
A1 Hosein, Fareeda
A1 Simsek, Burcin
A1 Maio, Michele
YR 2020
UL http://jitc.bmj.com/content/8/1/e000391.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.